22 April 2018

TIKOMED IS INTERVIEWED AT BIOSPRING ABOUT IBSOLVMIR FOR IMPROVED CELL-THERAPIES BY MIKE WARD

TikoMeds promising Phase 2 project for more efficient cell-therapies was presented at BioEurope Spring in Amsterdam. Below follows an interview by Mike Ward of Adam Bruce, Founder and CEO of TikoMed.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

30 November 2018
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
VIKEN, Sweden, November 19, 2018 (Newswire) -TIKOMED, a specialty pharmaceutical company developing IBsolvMIR, an infusion…
Read More
2 November 2018
First patient treated with ILB in TIKOMED’s clinical trial for ALS
Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
20 August 2018
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
SEE MORE